Slideshows Images Quizzes

Copyright © 2018 by RxList Inc. RxList does not provide medical advice, diagnosis or treatment. See additional information.

Trulicity

Last reviewed on RxList: 2/23/2021
Trulicity Side Effects Center

What Is Trulicity?

Trulicity (dulaglutide) is a human GLP-1 receptor agonist used as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

What Are Side Effects of Trulicity?

Common side effects of Trulicity include:

Dosage for Trulicity

The recommended initiating dose of Trulicity is 0.75 mg once weekly. The maximum recommended dose is 1.5 mg once weekly.

What Drugs, Substances, or Supplements Interact with Trulicity?

Trulicity may interact with other oral medications. Tell your doctor all medications and supplements you use.

Trulicity During Pregnancy and Breastfeeding

During pregnancy, Trulicity should be taken only if prescribed; it is unknown if it would affect a fetus. It is unknown if Trulicity passes into breast milk. Consult your doctor before breastfeeding.

Additional Information

Our Trulicity (dulaglutide) Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

QUESTION

______________ is another term for type 2 diabetes. See Answer
Trulicity Consumer Information

3 pharmacies near 20147 have coupons for Trulicity Pen (Brand Names:Trulicity for 0.5ML of 0.75MG/0.5ML)

CVS Pharmacy
CVS Pharmacy
$888.42

Est. Regular Price

$4565.57

with free coupon

View Coupon
Walgreens
Walgreens
$888.42

Est. Regular Price

$4682.66

with free coupon

View Coupon
Walmart Pharmacy
Walmart Pharmacy
$888.42

Est. Regular Price

$4746.96

with free coupon

View Coupon

Stop using dulaglutide and get emergency medical help if you have signs of an allergic reaction: hives; difficult breathing; feeling light-headed; swelling of your face, lips, tongue, or throat.

Call your doctor at once if you have:

  • pancreatitis--severe pain in your upper stomach spreading to your back, nausea and vomiting;
  • signs of a thyroid tumor--swelling or a lump in your neck, trouble swallowing, a hoarse voice, or if you feel short of breath;
  • low blood sugar--headache, hunger, weakness, sweating, confusion, irritability, dizziness, fast heart rate, or feeling jittery; or
  • kidney problems--little or no urination, swelling in your feet or ankles, feeling tired or short of breath.

Tell your doctor if you are sick with vomiting or diarrhea, or if you are sweating more than usual. You can easily become dehydrated while using dulaglutide. This can lead to kidney failure.

Common side effects may include:

  • nausea, vomiting, stomach pain;
  • diarrhea; or
  • loss of appetite.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Read the entire detailed patient monograph for Trulicity (Dulaglutide Injection, for Subcutaneous Use)

SLIDESHOW

Type 2 Diabetes: Signs, Symptoms, Treatments See Slideshow
Trulicity Professional Information

SIDE EFFECTS

The following serious reactions are described below or elsewhere in the prescribing information:

  • Risk of Thyroid C-cell Tumors [see WARNINGS AND PRECAUTIONS]
  • Pancreatitis [see WARNINGS AND PRECAUTIONS]
  • Hypoglycemia with Concomitant Use of Insulin Secretagogues or Insulin [see WARNINGS AND PRECAUTIONS]
  • Hypersensitivity Reactions [see WARNINGS AND PRECAUTIONS]
  • Acute Kidney Injury [see WARNINGS AND PRECAUTIONS]
  • Severe Gastrointestinal Disease [see WARNINGS AND PRECAUTIONS]

Clinical Studies Experience

Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in practice.

Pool Of Placebo-Controlled Trials

The data in Table 1 are derived from placebo-controlled trials [see Clinical Studies].

These data reflect exposure of 1670 patients to TRULICITY and a mean duration of exposure to TRULICITY of 23.8 weeks. Across the treatment arms, the mean age of patients was 56 years, 1% were 75 years or older and 53% were male. The population in these studies was 69% White, 7% Black or African American, 13% Asian; 30% were of Hispanic or Latino ethnicity. At baseline, the population had diabetes for an average of 8.0 years and had a mean HbA1c of 8.0%. At baseline, 2.5% of the population reported retinopathy. Baseline estimated renal function was normal or mildly impaired (eGFR ≥60 mL/min/1.73 m2) in 96.0% of the pooled study populations.

Table 1 shows common adverse reactions, excluding hypoglycemia, associated with the use of TRULICITY in a pool of placebo-controlled trials. These adverse reactions were not present at baseline, occurred more commonly on TRULICITY than on placebo, and occurred in at least 5% of patients treated with TRULICITY.

Table 1: Adverse Reactions in Placebo-Controlled Trials Reported in ≥5% of TRULICITY-Treated Patients

Adverse Reaction Placebo
(N=568)
%
TRULICITY 0.75 mg
(N=836)
%
TRULICITY 1.5 mg
(N=834)
%
Nausea 5.3 12.4 21.1
Diarrheaa 6.7 8.9 12.6
Vomitingb 2.3 6.0 12.7
Abdominal Painc 4.9 6.5 9.4
Decreased Appetite 1.6 4.9 8.6
Dyspepsia 2.3 4.1 5.8
Fatigued 2.6 4.2 5.6
a Includes diarrhea, fecal volume increased, frequent bowel movements.
b Includes retching, vomiting, vomiting projectile.
cIncludes abdominal discomfort, abdominal pain, abdominal pain lower, abdominal pain upper, abdominal tenderness, gastrointestinal pain.
d Includes fatigue, asthenia, malaise.
Note: Percentages reflect the number of patients that reported at least 1 treatment-emergent occurrence of the adverse reaction.

Gastrointestinal Adverse Reactions

In the pool of placebo-controlled trials, gastrointestinal adverse reactions occurred more frequently among patients receiving TRULICITY than placebo (placebo 21.3%, 0.75 mg 31.6%, 1.5 mg 41.0%). More patients receiving TRULICITY 0.75 mg (1.3%) and TRULICITY 1.5 mg (3.5%) discontinued treatment due to gastrointestinal adverse reactions than patients receiving placebo (0.2%). Investigators graded the severity of gastrointestinal adverse reactions occurring on 0.75 mg and 1.5 mg of TRULICITY as “mild” in 58% and 48% of cases, respectively, “moderate” in 35% and 42% of cases, respectively, or “severe” in 7% and 11% of cases, respectively.

In addition to the reactions in Table 1, the following adverse reactions were reported more frequently in TRULICITY-treated patients than placebo (frequencies listed, respectively, as: placebo; 0.75 mg; 1.5 mg): constipation (0.7%, 3.9%, 3.7%), flatulence (1.4%, 1.4%, 3.4%), abdominal distension (0.7%, 2.9%, 2.3%), gastroesophageal reflux disease (0.5%, 1.7%, 2.0%), and eructation (0.2%, 0.6%, 1.6%).

Pool Of Placebo-And Active-Controlled Trials

The occurrence of adverse reactions was also evaluated in a larger pool of patients with type 2 diabetes participating in 6 placebo-and active-controlled trials evaluating the use of TRULICITY as monotherapy and add-on therapy to oral medications or insulin [see Clinical Studies]. In this pool, a total of 3342 patients with type 2 diabetes were treated with TRULICITY for a mean duration of 52 weeks. The mean age of patients was 56 years, 2% were 75 years or older and 51% were male. The population in these studies was 71% White, 7% Black or African American, 11% Asian; 32% were of Hispanic or Latino ethnicity. At baseline, the population had diabetes for an average of 8.2 years and had a mean HbA1c of 7.6-8.5%. At baseline, 5.2% of the population reported retinopathy. Baseline estimated renal function was normal or mildly impaired (eGFR ≥60 mL/min/1.73 m2) in 95.7% of the TRULICITY population.

In the pool of placebo-and active-controlled trials, the types and frequency of common adverse reactions, excluding hypoglycemia, were similar to those listed in Table 1.

Other Adverse Reactions

Hypoglycemia

Table 2 summarizes the incidence of hypoglycemia in the placebo-controlled clinical studies: episodes with a glucose level <54 mg/dL with or without symptoms, and severe hypoglycemia, defined as an episode requiring the assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions.

Table 2: Incidence (%) of Hypoglycemia in Placebo-Controlled Trials

  Placebo TRULICITY
0.75 mg
TRULICITY
1.5 mg
Add-on to Metformin
(26 weeks) N=177 N=302 N=304
  Hypoglycemia with a glucose level <54 mg/dL 0 0.3 0.7
  Severe hypoglycemia 0 0 0
Add-on to Metformin + Pioglitazone
  (26 weeks) N=141 N=280 N=279
  Hypoglycemia with a glucose level <54 mg/dL 1.4 2.1 0
  Severe hypoglycemia 0 0 0
  Add-on to Glimepiride
  (24 weeks) N=60 - N=239
  Hypoglycemia with a glucose level <54 mg/dL 0 - 3.3
  Severe hypoglycemia 0 - 0
In Combination with Insulin Glargine ± Metformin
  (28 weeks) N=150 - N=150
  Hypoglycemia with a glucose level <54 mg/dL 9.3 - 14.7
  Severe hypoglycemia 0 - 0.7
Add-on to SGLT2i ± Metformin
  (24 weeks) N=140 N=141 N=142
  Hypoglycemia with a glucose level <54 mg/dL 0.7 0.7 0.7
  Severe hypoglycemia 0 0.7 0

Hypoglycemia was more frequent when TRULICITY was used in combination with a sulfonylurea or insulin than when used with non-secretagogues [see WARNINGS AND PRECAUTIONS]. In a 78-week clinical trial, hypoglycemia (glucose level <54 mg/dL) occurred in 20% and 21% of patients when TRULICITY 0.75 mg and 1.5 mg, respectively, were co-administered with a sulfonylurea. Severe hypoglycemia occurred in 0% and 0.7% of patients when TRULICITY 0.75 mg and 1.5 mg, respectively, were co-administered with a sulfonylurea. In a 52-week clinical trial, hypoglycemia (glucose level <54 mg/dL) occurred in 77% and 69% of patients when TRULICITY 0.75 mg and 1.5 mg, respectively, were co-administered with prandial insulin. Severe hypoglycemia occurred in 2.7% and 3.4% of patients when TRULICITY 0.75 mg and 1.5 mg, respectively, were co-administered with prandial insulin. Refer to Table 2 for the incidence of hypoglycemia in patients treated in combination with basal insulin glargine.

Heart Rate Increase and Tachycardia-Related Adverse Reactions

TRULICITY 0.75 mg and 1.5 mg resulted in a mean increase in heart rate (HR) of 2-4 beats per minute (bpm). The long-term clinical effects of the increase in HR have not been established [see WARNINGS AND PRECAUTIONS].

Adverse reactions of sinus tachycardia were reported more frequently in patients exposed to TRULICITY. Sinus tachycardia was reported in 3.0%, 2.8%, and 5.6% of patients treated with placebo, TRULICITY 0.75 mg and TRULICITY 1.5 mg, respectively. Persistence of sinus tachycardia (reported at more than 2 visits) was reported in 0.2%, 0.4% and 1.6% of patients treated with placebo, TRULICITY 0.75 mg and TRULICITY 1.5 mg, respectively. Episodes of sinus tachycardia, associated with a concomitant increase from baseline in heart rate of ≥15 beats per minute, were reported in 0.7%, 1.3% and 2.2% of patients treated with placebo, TRULICITY 0.75 mg and TRULICITY 1.5 mg, respectively.

Hypersensitivity

Systemic hypersensitivity adverse reactions, sometimes severe (e.g., severe urticaria, systemic rash, facial edema, lip swelling), occurred in 0.5% of patients on TRULICITY in the four Phase 2 and five Phase 3 studies.

Injection-site Reactions

In the placebo-controlled studies, injection-site reactions (e.g., injection-site rash, erythema) were reported in 0.5% of TRULICITY-treated patients and in 0.0% of placebo-treated patients.

PR Interval Prolongation and Adverse Reactions of First-Degree Atrioventricular (AV) Block

A mean increase from baseline in PR interval of 2-3 milliseconds was observed in TRULICITY-treated patients in contrast to a mean decrease of 0.9 milliseconds in placebo-treated patients. The adverse reaction of first-degree AV block occurred more frequently in patients treated with TRULICITY than placebo (0.9%, 1.7% and 2.3% for placebo, TRULICITY 0.75 mg and TRULICITY 1.5 mg, respectively). On electrocardiograms, a PR interval increase to at least 220 milliseconds was observed in 0.7%, 2.5% and 3.2% of patients treated with placebo, TRULICITY 0.75 mg and TRULICITY 1.5 mg, respectively.

Amylase and Lipase Increase

Patients exposed to TRULICITY had mean increases from baseline in lipase and/or pancreatic amylase of 14% to 20%, while placebo-treated patients had mean increases of up to 3%.

Immunogenicity

Across four Phase 2 and five Phase 3 clinical studies, 64 (1.6%) TRULICITY-treated patients developed anti-drug antibodies (ADAs) to the active ingredient in TRULICITY (i.e., dulaglutide).

Of the 64 dulaglutide-treated patients that developed dulaglutide ADAs, 34 patients (0.9% of the overall population) had dulaglutide-neutralizing antibodies, and 36 patients (0.9% of the overall population) developed antibodies against native GLP-1.

The detection of antibody formation is highly dependent on the sensitivity and specificity of the assay. Additionally, the observed incidence of antibody (including neutralizing antibody) positivity in an assay may be influenced by several factors including assay methodology, sample handling, timing of sample collection, concomitant medications, and underlying disease. For these reasons, the incidence of antibodies to dulaglutide cannot be directly compared with the incidence of antibodies of other products.

Postmarketing Experience

The following additional adverse reactions have been reported during post-approval use of TRULICITY. Because these events are reported voluntarily from a population of uncertain size, it is generally not possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Read the entire FDA prescribing information for Trulicity (Dulaglutide Injection, for Subcutaneous Use)

Related Resources for Trulicity

© Trulicity Patient Information is supplied by Cerner Multum, Inc. and Trulicity Consumer information is supplied by First Databank, Inc., used under license and subject to their respective copyrights.

QUESTION

______________ is another term for type 2 diabetes. See Answer

Health Solutions From Our Sponsors